Pharvaris (PHVS) Stock Price, News & Analysis

Company Overview

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials. Pharvaris is also developing an on-demand version of its kallikrein inhibitor to provide patients with an acute treatment option. Both candidates represent the company’s effort to offer fully oral alternatives to current injectable therapies.

Founded in 2016 and headquartered in Leiden, the Netherlands, Pharvaris maintains a presence in the United States to support clinical development and regulatory engagement. Since completing its initial public offering on the NASDAQ in 2020, the company has expanded its research partnerships and scaled its operations to prepare for potential commercialization.

Pharvaris is led by an experienced management team with deep expertise in rare disease drug development, medicinal chemistry and clinical operations. The company’s board and advisory committees include professionals with backgrounds in immunology, hematology and regulatory affairs, guiding its strategy toward delivering innovative treatments to patients worldwide.

Key Stats

• Today's Range: $30.69 to $33.20
• 50-Day Range: $25.34 to $32.94
• 52-Week Range: $15.34 to $33.33
• Volume: 480,550 shs
• Average Volume: 381,846 shs
• Market Capitalization: $2.01 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $49.18
• Consensus Rating: Moderate Buy

Pharvaris Stock Analysis - MarketRank™

Pharvaris scored higher than 78% of companies evaluated by MarketBeat, and ranked 157th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Pharvaris has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on no strong buy ratings, 10 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Pharvaris has a consensus price target of $49.18, representing about 60.2% upside from its current price of $30.70.

Amount of Analyst Coverage

Pharvaris has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Pharvaris are expected to grow in the coming year, from ($3.14) to ($2.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pharvaris is -9.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pharvaris is -9.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pharvaris has a P/B Ratio of 7.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.61% of the float of Pharvaris has been sold short.

Short Interest Ratio / Days to Cover

Pharvaris has a short interest ratio ("days to cover") of 3.48, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pharvaris has recently decreased by 6.75%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pharvaris does not currently pay a dividend.

Dividend Growth

Pharvaris does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.59

News Sentiment

Pharvaris has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Pharvaris this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for PHVS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Pharvaris insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,489,587.00 in company stock.

Percentage Held by Insiders

11.84% of the stock of Pharvaris is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Pharvaris has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 5/15/2026
• RBC Capital Markets Global Healthcare Conference 2026: 5/20/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PHVS
• CIK: 1830487
• Web: www.pharvaris.com
• Phone: 31-71-203-6410
• Fax: N/A
• Employees: 30
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Pharvaris: $49.18
• High Price Target: $74.00
• Low Price Target: $30.00
• Potential Upside/Downside: +60.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.69
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$198.79 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -67.56%
• Return on Assets: -61.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.24
• Quick Ratio: 10.11

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.23 per share
• Price / Book: 7.26

Miscellaneous

• Outstanding Shares: 65,408,000
• Free Float: 57,664,000
• Market Cap: $2.01 billion
• Optionable: Not Optionable
• Beta: -2.34